Circulating CGRP as a diagnostic biomarker in female migraine patients: a single-center case-control study

Plain-language guide to PMID 41107707 (2025): observational study of CGRP (Calcitonin Gene-Related Peptide) in 184 patients, migraine.

Key Facts

PMID: 41107707
Journal: The journal of headache and pain
Year: 2025
Study type: Observational Study
Authors: Huang Q et al. (14 authors)
DOI: 10.1186/s10194-025-02166-1

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of CGRP (Calcitonin Gene-Related Peptide) in the context of migraine, published as an observational study.

Given higher prevalence, frequency and severity of migraine in women, this study aims to investigate the diagnostic and therapeutic value of plasma CGRP in female migraine patients.

Why It Was Studied

Migraine constitutes the predominant cause of disability-adjusted life years (DALYs), yet remains diagnostically challenging due to lack of biomarkers.

Calcitonin gene-related peptide (CGRP) has been recognized as the pathophysiological cornerstone of migraine.

Who Took Part

The study group was 184 patients.

By PubMed's age tags, the people studied were adults and middle-aged adults, women only.

This prospective observational study enrolled 184 female migraine patients and 85 healthy controls.

Additionally, patients who received the CGRP receptor antagonist rimegepant during the acute phase of migraine were analyzed.

How the Study Was Run

CGRP concentrations were quantitatively analyzed using a magnetic particle chemiluminescent immunoassay (MP-CLIA) platform.

High- and low-expression subgroups were stratified according to a predefined cutoff value of serum CGRP levels.

What Was Measured

Topics PubMed links to this paper include Migraine Disorders, Case-Control Studies, Calcitonin Gene-Related Peptide, Biomarkers, Calcitonin Gene-Related Peptide Receptor Antagonists, Pyridines and Piperidines.

Author keywords: CGRP, Female and Rimegepant.

What This Means in Plain Language

This is an observational study of CGRP (Calcitonin Gene-Related Peptide) in 184 patients in people with migraine.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (The journal of headache and pain), a journal based in England.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.

Our Notes on the Compound

CGRP (Calcitonin Gene-Related Peptide): A 37-amino-acid neuropeptide that widens blood vessels and is involved in migraine; given in research provocation studies.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.